尽管第三季度的收益和收入略低于预期，但 Taysha Gene Therapies 的股价仍上涨。 Taysha Gene Therapies' stock rose despite Q3 earnings and revenue slightly missing estimates.

Taysha基因治疗机构报告,Q3收入为0.07 EPS,略微超出估计0.08美元。 Taysha Gene Therapies reported Q3 earnings of $0.07 EPS, slightly beating estimates of $0.08. 收入为202万美元,低于预期收入205万美元。 Revenue was $2.02 million, below the expected $2.05 million. 尽管收入减少,财政衡量指标为负数,但库存增至1.63美元。 Despite lower revenue and negative financial metrics, the stock increased to $1.63. 一些分析家的“买入”评级为“买入”,平均目标价格为6.63美元。 Several analysts have a "buy" rating with an average target price of $6.63. Taysha着重于中枢神经系统疾病的基因疗法。 Taysha focuses on gene therapies for central nervous system diseases.